GNRH1 and diabetes mellitus: Although significant differences were observed between therapy classes regarding hypertension, no significant differences have been observed in the relative increase of CVD and diabetes from index quarter to follow-up period between GnRH antagonist compared to GnRH agonists and hybrids.